Benjamin H. Lowentritt, MD, FACS, Highlights 18F-rhPSMA-7.3 Detection Rates by Subgroup in Suspected Recurrent Prostate Cancer

Video

PSMA-targeting PET ligand 18F-rhPSMA-7.3 yielded high detection rates for patients with recurrent prostate cancer regardless of factors such as PSA levels, PSA doubling time, or Gleason scores, according to Benjamin H. Lowenritt, MD, FACS.

CancerNetwork® spoke with Benjamin H. Lowenritt, MD, FACS, a practicing urologist at Chesapeake Urology in Baltimore, Maryland, about findings from the phase 3 SPOTLIGHT study (NCT04186845), examining the impact of clinical factors on the detection rate of 18F-rhPSMA-7.3 in suspected recurrent prostate cancer, that were presented at the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting. According to Lowenritt, the agent produced high detection rates across patient subgroups based on factors such as prostate-specific antigen (PSA) level, PSA doubling time, and initial Gleason scores.

Transcript:

What we know about patients who recur is that we do see all different patterns of recurrence, some that happen more quickly, and some that happen over more of a time period. We also find the patients at different points—both specifically with their PSA levels, as well as their PSA doubling time—may have had a history of higher or lower grade cancer at their initial diagnosis. We looked at all of these [factors], [including] the PSA level, the PSA doubling time, their initial Gleason score, and whether they had surgery or radiation initially, and there was an overall very high level of performance and detection rates across all of those subgroups.

There certainly is a component of the absolute PSA level where you see the higher the PSA, the higher the detection rate but in the entire cohort that was studied—where we assessed detection rate data using a majority of blinded central readers—83% of patients who were imaged had disease detected. All of this was very positive and shows the value of having this novel PET agent in identifying sites of recurrence.

Reference

Lowentritt, B. Impact of clinical factors on 18F-rhPSMA-7.3 detection rates in men with recurrent prostate cancer: findings from the phase 3 SPOTLIGHT study. Presented at 2022 American Society for Radiation Oncology Annual Meeting (ASTRO); October 23-26, 2022; San Antonio, TX. Abstract 1049. Accessed November 3, 2022.

Related Videos
The use of a single-port robot may allow for surgically treating more patients with head and neck cancer in a more timely manner, according to Hilary McCrary, MD, MPH.
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
Patients with KRAS G12C-mutated non–small cell lung cancer who have brain metastases or intolerability of intravenous infusion may be more suitable to receive a small molecule inhibitor compared with chemotherapy, says Sandip P. Patel, MD.
Treatment with sotorasib or adagrasib appears to be more tolerable among patients with KRAS G12C-mutated non–small cell lung cancer compared with docetaxel, according to Sandip Patel, MD.
Notions of blame around smoking may be a prominent factor in patients with lung cancer feeling stigmatized for developing their disease, according to Lisa Carter-Bawa PhD, MPH, APRN, ANP-C, FAAN.
Related Content